IP Library Granted Patent US 11,156,608
Granted Patent B2
US 11,156,608 · App. 14/774,883 · Granted Oct 26, 2021

Method for the site-specific covalent cross-linking of antibodies to surfaces

Inventors: Andrew Tsourkas (Bryn Mawr, PA); James Z. Hui (Philadelphia, PA)
Assignee: THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA
G01N33/54353A61K47/62A61K47/65A61K47/6855A61K49/1875C07K14/31C07K17/00C07K17/06G01N33/582C07K2319/30
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,156,608
App. No.
14/774,883
Granted
Oct 26, 2021
Kind
B2
Abstract

This invention relates to conjugate antibody, drug and nanoparticle compositions and methods of generating the same. This invention further relates to methods of using same for imaging, diagnosing or treating a disease.

Claims (25)

1. A conjugate composition comprising a variant of protein Z comprising a photoreactive crosslinker that permits specific binding to an immunoglobulin Fc region, wherein the variant of protein Z comprises an amino acid sequence which has at least 90% identity to the sequence set forth in SEQ ID NO: 1 with the photoreactive crosslinker substituted for or introduced at F13, Q32, K35, N28, N23, or L17.

2. The composition of claim 1 , wherein said immunoglobulin is IgG.

3. The composition of claim 1 , wherein said photoreactive crosslinker is a UV-active non-natural amino acid.

4. The composition of claim 3 , wherein said amino acid is benzoylphenylalanine (BPA).

5. The composition of claim 1 , wherein said composition comprises a fusion protein comprising the variant of protein Z fused to an additional polypeptide.

6. The composition of claim 5 , wherein said fusion protein further comprises a moiety for expressed protein ligation.

7. The composition of claim 6 , wherein said moiety is an intein-MPB group or a sortase-Hisx6 group.

8. The composition of claim 1 , wherein said variant of protein Z is attached to a peptide following an expressed protein ligation.

9. The composition of claim 8 , wherein said peptide is attached to an additional polypeptide of interest via a crosslinker.

10. The composition of claim 8 , wherein said peptide comprises a chemical moiety that permits chemical binding to a corresponding chemical group.

11. The composition of claim 10 , wherein said chemical binding is click chemistry or maleimide chemistry.

12. The composition of claim 8 , wherein said variant of protein Z is specifically attached in the proper orientation to a surface, polypeptide, a nanoparticle, or a drug via said click chemistry.

13. The composition of claim 9 , wherein said additional polypeptide is a drug, an imaging agent, or a toxin.

14. A bacterial cell for recombinantly expressing the composition of claim 8 .

15. A bacterial cell for recombinantly expressing the composition of claim 1 .

16. A nanoparticle conjugate comprising the composition of claim 1 .

17. A modified antibody complex comprising the composition of claim 1 .

18. The modified antibody complex of claim 17 , comprising a drug-antibody combination.

19. A method of imaging a biological sample, the method comprising the step of contacting said biological sample with the nanoparticle conjugate of claim 16 , wherein said contacting permits imaging of said biological sample.

20. A method of imaging a biological sample, the method comprising the step of contacting a biological sample with said antibody complex of claim 17 , wherein said contacting permits imaging of said biological sample.

21. The method of claim 19 , wherein said biological sample is associated with a disease.

22. The method of claims 21 , wherein imaging said biological sample permits diagnosing a disease.

23. The method of claims 21 , wherein said biological sample is tissue, DNA, sperm, sera, blood, cerebrospinal fluid, or a biomarker.

24. A method of producing the conjugate composition of claim 1 , the method comprising the step of recombinantly expressing said conjugate composition in a bacterial cell.

25. The composition of claim 4 , wherein the variant is K35BPA or L17BPA.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 29, 2018
From: TSOURKAS, ANDREW; HUI, JAMES Z.
To: THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA
Reel/Frame 047629/0942 →
CONFIRMATORY LICENSE Recorded Jun 27, 2016
From: UNIVERSITY OF PENNSYLVANIA
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 039166/0963 →
Continuity (2)
Provisional Application 61800926 · Mar 15, 2013
Related Publication 20160041157A1 · Feb 11, 2016
Cited By (4)
US 12,269,847 US 12,270,809 US 12,637,664 US 12,692,483